Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
TransDigm Group INC incurred term loan of $800 million with Goldman Sachs Bank USA at Term SOFR plus an applicable margin of 2.50% maturing February 13, 2033.
- Instrument
- term loan
- Principal
- $800 million
- Counterparty
- Goldman Sachs Bank USA
- Rate
- Term SOFR plus an applicable margin of 2.50%
- Maturity
- February 13, 2033
- Event
- incurrence
Exact text from the filing
$800 million of new tranche N term loans (the “New Term Loans”) maturing February 13, 2033
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
TransDigm Group INC incurred senior notes of $1,200 million with The Bank of New York Mellon Trust Company, N.A. at 6.125% per annum maturing July 31, 2034.
- Instrument
- senior notes
- Principal
- $1,200 million
- Counterparty
- The Bank of New York Mellon Trust Company, N.A.
- Rate
- 6.125% per annum
- Maturity
- July 31, 2034
- Event
- incurrence
Exact text from the filing
completed the previously announced offerings of an aggregate of $2,000 million of new debt, consisting of $1,200 million of 6.125% Senior Subordinated Notes maturing July 31, 2034
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
TransDigm Group INC amended Amendment No. 20 and Incremental Term Loan Assumption Agreement with Goldman Sachs Bank USA valued at $800,000,000 Tranche N Term Loans (effective 2026-02-13).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Goldman Sachs Bank USA
- Value
- $800,000,000 Tranche N Term Loans
- Effective
- 2026-02-13
Exact text from the filing
AMENDMENT NO. 20 and INCREMENTAL TERM LOAN ASSUMPTION AGREEMENT dated as of February 13, 2026, relating to the SECOND AMENDED AND RESTATED CREDIT AGREEMENT dated as of June 4, 2014, among TRANSDIGM INC., TRANSDIGM GROUP INCORPORATED, THE SUBSIDIARIES OF TRANSDIGM INC. FROM TIME TO TIME PARTY THERETO, THE LENDERS PARTY THERETO and GOLDMAN SACHS BANK USA, as Administrative Agent and Collateral Agent
View on SEC.gov